| Literature DB >> 28163231 |
Sharon S Y Leung1, Thaigarajan Parumasivam1, Fiona G Gao1, Elizabeth A Carter2, Nicholas B Carrigy3, Reinhard Vehring3, Warren H Finlay3, Sandra Morales4, Warwick J Britton5, Elizabeth Kutter6, Hak-Kim Chan7.
Abstract
This study aimed to develop inhalable powders containing phages active against antibiotic-resistant Pseudomonas aeruginosa for pulmonary delivery. A Pseudomonas phage, PEV2, was spray dried into powder matrices comprising of trehalose (0-80%), mannitol (0-80%) and l-leucine (20%). The resulting powders were stored at various relative humidity (RH) conditions (0, 22 and 60% RH) at 4°C. The phage stability and in vitro aerosol performance of the phage powders were examined at the time of production and after 1, 3 and 12 months storage. After spray drying, a total of 1.3 log titer reduction in phage was observed in the formulations containing 40%, 60% and 80% trehalose, whereas 2.4 and 5.1 log reductions were noted in the formulations containing 20% and no trehalose, respectively. No further reduction in titer occurred for powders stored at 0 and 22% RH even after 12 months, except the formulation containing no trehalose. The 60% RH storage condition had a destructive effect such that no viable phages were detected after 3 and 12 months. When aerosolised, the total lung doses for formulations containing 40%, 60% and 80% trehalose were similar (in the order of 105 pfu). The results demonstrated that spray drying is a suitable method to produce stable phage powders for pulmonary delivery. A powder matrix containing ≥40% trehalose provided good phage preservation and aerosol performances after storage at 0 and 22% RH at 4°C for 12 months.Entities:
Keywords: MDR; Multi-drug resistance; PEV2; Phage; Pulmonary infection; Spray drying
Mesh:
Substances:
Year: 2017 PMID: 28163231 PMCID: PMC5389863 DOI: 10.1016/j.ijpharm.2017.01.060
Source DB: PubMed Journal: Int J Pharm ISSN: 0378-5173 Impact factor: 5.875